VINDESINE IN BRONCHOGENIC-CARCINOMA - A PHASE-II TRIAL

Google Scholar
  • 1 January 1982
    • journal article
    • research article
    • Vol. 5  (1) , 41-44
Abstract
Patients (27) with advanced bronchogenic carcinoma were treated with vindesine, 3 mg/m2/wk. Twenty-three patients were evaluable for response. Two of 6 patients with small-cell carcinoma and one of 17 patients with non-small-cell carcinom had partial responses. Two other patients with non-small-cell carcinoma, had minor responses. The duration of the responses was 2-4 mo. Neurologic toxicity occurred in 14 patients and was mild except in 2 patients. There was a median Hb fall of 2.2 g/dl and a median leukocyte nadir of 2800/.mu.l during vindesine therapy. Thrombocytopenia occurred in 2 patients and mild thrombocytosis occurred in 10 patients. Seven patients experienced phlebitis or cellulitis at the site of drug administration which could be prevented with small doses of i.v. methylprednisolone. These results suggest that vindesine is well tolerated and possesses some activity in patients with previously treated bronchogenic carcinoma.